BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Lapi F, Marconi E, Simonetti M, Baldo V, Rossi A, Sessa A, Cricelli C. Adjuvanted versus nonadjuvanted influenza vaccines and risk of hospitalizations for pneumonia and cerebro/cardiovascular events in the elderly. Expert Rev Vaccines 2019;18:663-70. [PMID: 31155968 DOI: 10.1080/14760584.2019.1622418] [Cited by in Crossref: 16] [Cited by in F6Publishing: 15] [Article Influence: 5.3] [Reference Citation Analysis]
Number Citing Articles
1 Buchy P, Badur S. Who and when to vaccinate against influenza. International Journal of Infectious Diseases 2020;93:375-87. [DOI: 10.1016/j.ijid.2020.02.040] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 5.5] [Reference Citation Analysis]
2 Biswas A, Chakrabarti AK, Dutta S. Current challenges: from the path of “original antigenic sin” towards the development of universal flu vaccines: Flu vaccine efficacy encounters significant hurdles from pre-existing immunity of the host suggesting assessment of host immunity before vaccination. International Reviews of Immunology 2020;39:21-36. [DOI: 10.1080/08830185.2019.1685990] [Cited by in Crossref: 5] [Cited by in F6Publishing: 7] [Article Influence: 1.7] [Reference Citation Analysis]
3 Grohskopf LA, Alyanak E, Broder KR, Walter EB, Fry AM, Jernigan DB. Prevention and Control of Seasonal Influenza with Vaccines: Recommendations of the Advisory Committee on Immunization Practices - United States, 2019-20 Influenza Season. MMWR Recomm Rep 2019;68:1-21. [PMID: 31441906 DOI: 10.15585/mmwr.rr6803a1] [Cited by in Crossref: 195] [Cited by in F6Publishing: 179] [Article Influence: 65.0] [Reference Citation Analysis]
4 Coleman BL, Sanderson R, Haag MDM, McGovern I. Effectiveness of the MF59-adjuvanted trivalent or quadrivalent seasonal influenza vaccine among adults 65 years of age or older, a systematic review and meta-analysis. Influenza Other Respir Viruses 2021. [PMID: 34081398 DOI: 10.1111/irv.12871] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
5 McConeghy KW, Davidson HE, Canaday DH, Han L, Saade E, Mor V, Gravenstein S. Cluster-randomized trial of adjuvanted vs. non-adjuvanted trivalent influenza vaccine in 823 U.S. nursing homes. Clin Infect Dis 2020:ciaa1233. [PMID: 32882710 DOI: 10.1093/cid/ciaa1233] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
6 Pelton SI, Divino V, Postma MJ, Shah D, Mould-Quevedo J, DeKoven M, Krishnarajah G. A retrospective cohort study assessing relative effectiveness of adjuvanted versus high-dose trivalent influenza vaccines among older adults in the United States during the 2018-19 influenza season. Vaccine 2021;39:2396-407. [PMID: 33810903 DOI: 10.1016/j.vaccine.2021.03.054] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
7 Lapi F, Domnich A, Marconi E, Rossi A, Grattagliano I, Lagolio E, Medea G, Sessa A, Cricelli I, Icardi G, Cricelli C. Predicting the risk of severe COVID-19 outcomes in primary care: development and validation of a vulnerability index for equitable allocation of effective vaccines. Expert Rev Vaccines 2021;:1-8. [PMID: 34913796 DOI: 10.1080/14760584.2022.2019582] [Reference Citation Analysis]
8 Cocchio S, Gallo T, Del Zotto S, Clagnan E, Iob A, Furlan P, Fonzo M, Bertoncello C, Baldo V. Preventing the Risk of Hospitalization for Respiratory Complications of Influenza among the Elderly: Is There a Better Influenza Vaccination Strategy? A Retrospective Population Study. Vaccines (Basel) 2020;8:E344. [PMID: 32605238 DOI: 10.3390/vaccines8030344] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
9 Izurieta HS, Chillarige Y, Kelman J, Wei Y, Lu Y, Xu W, Lu M, Pratt D, Wernecke M, MaCurdy T, Forshee R. Relative Effectiveness of Influenza Vaccines Among the United States Elderly, 2018-2019. J Infect Dis 2020;222:278-87. [PMID: 32100009 DOI: 10.1093/infdis/jiaa080] [Cited by in Crossref: 20] [Cited by in F6Publishing: 19] [Article Influence: 20.0] [Reference Citation Analysis]
10 Dugan HL, Henry C, Wilson PC. Aging and influenza vaccine-induced immunity. Cell Immunol 2020;348:103998. [PMID: 31733824 DOI: 10.1016/j.cellimm.2019.103998] [Cited by in Crossref: 27] [Cited by in F6Publishing: 31] [Article Influence: 9.0] [Reference Citation Analysis]
11 Grohskopf LA, Alyanak E, Ferdinands JM, Broder KR, Blanton LH, Talbot HK, Fry AM. Prevention and Control of Seasonal Influenza with Vaccines: Recommendations of the Advisory Committee on Immunization Practices, United States, 2021-22 Influenza Season. MMWR Recomm Rep 2021;70:1-28. [PMID: 34448800 DOI: 10.15585/mmwr.rr7005a1] [Cited by in Crossref: 6] [Article Influence: 6.0] [Reference Citation Analysis]
12 Pelton SI, Divino V, Shah D, Mould-Quevedo J, DeKoven M, Krishnarajah G, Postma MJ. Evaluating the Relative Vaccine Effectiveness of Adjuvanted Trivalent Influenza Vaccine Compared to High-Dose Trivalent and Other Egg-Based Influenza Vaccines among Older Adults in the US during the 2017-2018 Influenza Season. Vaccines (Basel) 2020;8:E446. [PMID: 32784684 DOI: 10.3390/vaccines8030446] [Cited by in Crossref: 3] [Cited by in F6Publishing: 5] [Article Influence: 1.5] [Reference Citation Analysis]
13 Strain WD, Mansi J, Boikos C, Boivin M, Fisher WA. Achieving Influenza Vaccine Uptake Target in Canada via a Pharmacy-Led Telephone Discussion during the 2019-2020 Season. Vaccines (Basel) 2021;9:312. [PMID: 33810215 DOI: 10.3390/vaccines9040312] [Reference Citation Analysis]
14 Boikos C, Imran M, Nguyen VH, Ducruet T, Sylvester GC, Mansi JA. Effectiveness of the Adjuvanted Influenza Vaccine in Older Adults at High Risk of Influenza Complications. Vaccines (Basel) 2021;9:862. [PMID: 34451987 DOI: 10.3390/vaccines9080862] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
15 Machado MAA, Moura CS, Abrahamowicz M, Ward BJ, Pilote L, Bernatsky S. Relative effectiveness of influenza vaccines in elderly persons in the United States, 2012/2013-2017/2018 seasons. NPJ Vaccines 2021;6:108. [PMID: 34429431 DOI: 10.1038/s41541-021-00373-w] [Reference Citation Analysis]
16 Boikos C, Fischer L, O'Brien D, Vasey J, Sylvester GC, Mansi JA. Relative Effectiveness of Adjuvanted Trivalent Inactivated Influenza Vaccine Versus Egg-derived Quadrivalent Inactivated Influenza Vaccines and High-dose Trivalent Influenza Vaccine in Preventing Influenza-related Medical Encounters in US Adults ≥ 65 Years During the 2017-2018 and 2018-2019 Influenza Seasons. Clin Infect Dis 2021;73:816-23. [PMID: 33605977 DOI: 10.1093/cid/ciab152] [Cited by in Crossref: 4] [Cited by in F6Publishing: 1] [Article Influence: 4.0] [Reference Citation Analysis]
17 Grohskopf LA, Alyanak E, Broder KR, Blanton LH, Fry AM, Jernigan DB, Atmar RL. Prevention and Control of Seasonal Influenza with Vaccines: Recommendations of the Advisory Committee on Immunization Practices - United States, 2020-21 Influenza Season. MMWR Recomm Rep 2020;69:1-24. [PMID: 32820746 DOI: 10.15585/mmwr.rr6908a1] [Cited by in Crossref: 72] [Cited by in F6Publishing: 78] [Article Influence: 36.0] [Reference Citation Analysis]